132 related articles for article (PubMed ID: 9703265)
1. Antitumor activity of 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization.
Asai T; Kurohane K; Shuto S; Awano H; Matsuda A; Tsukada H; Namba Y; Okada S; Oku N
Biol Pharm Bull; 1998 Jul; 21(7):766-71. PubMed ID: 9703265
[TBL] [Abstract][Full Text] [Related]
2. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC.
Asai T; Miyazawa S; Maeda N; Hatanaka K; Katanasaka Y; Shimizu K; Shuto S; Oku N
Cancer Sci; 2008 May; 99(5):1029-33. PubMed ID: 18294280
[TBL] [Abstract][Full Text] [Related]
3. Targeting and anti-tumor efficacy of liposomal 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma.
Asai T; Shuto S; Matsuda A; Kakiuchi T; Ohba H; Tsukada H; Oku N
Cancer Lett; 2001 Jan; 162(1):49-56. PubMed ID: 11121862
[TBL] [Abstract][Full Text] [Related]
4. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
Kondo M; Asai T; Katanasaka Y; Sadzuka Y; Tsukada H; Ogino K; Taki T; Baba K; Oku N
Int J Cancer; 2004 Jan; 108(2):301-6. PubMed ID: 14639619
[TBL] [Abstract][Full Text] [Related]
5. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.
Asai T; Shimizu K; Kondo M; Kuromi K; Watanabe K; Ogino K; Taki T; Shuto S; Matsuda A; Oku N
FEBS Lett; 2002 Jun; 520(1-3):167-70. PubMed ID: 12044891
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of vincristine encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma.
Tokudome Y; Oku N; Doi K; Namba Y; Okada S
Biochim Biophys Acta; 1996 Feb; 1279(1):70-4. PubMed ID: 8624364
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice.
Oku N; Doi K; Namba Y; Okada S
Int J Cancer; 1994 Aug; 58(3):415-9. PubMed ID: 8050822
[TBL] [Abstract][Full Text] [Related]
8. In vivo trafficking of long-circulating liposomes in tumour-bearing mice determined by positron emission tomography.
Oku N; Tokudome Y; Tsukada H; Kosugi T; Namba Y; Okada S
Biopharm Drug Dispos; 1996 Jul; 17(5):435-41. PubMed ID: 8830978
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of reticuloendothelial system (RES)-avoiding liposomes containing a phospholipid analogue of 5-fluorouracil, dipalmitoylphosphatidylfluorouridine, in Meth A sarcoma-bearing mice.
Doi K; Oku N; Toyota T; Shuto S; Sakai A; Itoh H; Okada S
Biol Pharm Bull; 1994 Oct; 17(10):1414-6. PubMed ID: 7874068
[TBL] [Abstract][Full Text] [Related]
10. Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography.
Oku N; Tokudome Y; Tsukada H; Okada S
Biochim Biophys Acta; 1995 Aug; 1238(1):86-90. PubMed ID: 7654755
[TBL] [Abstract][Full Text] [Related]
11. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.
Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A
J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692
[TBL] [Abstract][Full Text] [Related]
12. Tumor accumulation of novel RES-avoiding liposomes.
Oku N; Namba Y; Okada S
Biochim Biophys Acta; 1992 Jun; 1126(3):255-60. PubMed ID: 1637853
[TBL] [Abstract][Full Text] [Related]
13. Glucuronate-modified liposomes with prolonged circulation time.
Namba Y; Sakakibara T; Masada M; Ito F; Oku N
Chem Pharm Bull (Tokyo); 1990 Jun; 38(6):1663-6. PubMed ID: 2208378
[TBL] [Abstract][Full Text] [Related]
14. Angiogenic vessel-targeting DDS by liposomalized oligopeptides.
Asai T; Oku N
Methods Mol Biol; 2010; 605():335-47. PubMed ID: 20072892
[TBL] [Abstract][Full Text] [Related]
15. Delivery of contrast agents for positron emission tomography imaging by liposomes.
Oku N
Adv Drug Deliv Rev; 1999 Apr; 37(1-3):53-61. PubMed ID: 10837726
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
17. Application of long-circulating liposomes to cancer photodynamic therapy.
Oku N; Saito N; Namba Y; Tsukada H; Dolphin D; Okada S
Biol Pharm Bull; 1997 Jun; 20(6):670-3. PubMed ID: 9212988
[TBL] [Abstract][Full Text] [Related]
18. Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080.
Obata T; Endo Y; Tanaka M; Matsuda A; Sasaki T
Cancer Lett; 1998 Jan; 123(1):53-61. PubMed ID: 9461018
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).
Azuma A; Huang P; Matsuda A; Plunkett W
Biochem Pharmacol; 2001 Jun; 61(12):1497-507. PubMed ID: 11377379
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W
Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
